What Regenecare HA Spray Treats: Main Uses and Benefits

The product is considered relevant for providing temporary, localized symptomatic relief for symptoms related to inflammatory or irritative states of the skin. The active ingredient may assist with managing the overall symptom load in conditions presenting with acute episodes of discomfort. This support is often used when short-term symptomatic assistance is needed for minor dermal trauma, environmental exposure, and localized skin irritation.

---

Therapeutic Scope

The formulation is commonly used across conditions presenting with acute episodes of distressing symptoms, such as small cuts, scrapes, and abrasions. It is also relevant for managing the discomfort, tenderness, and burning sensation associated with first-degree sunburn and for assisting with intense pruritus (itching) from insect bites or contact with irritating plants.

“This product contributes to easing the overall symptom load and may help patients cope more steadily with temporary skin distress.”

---

Patient Benefit

By addressing these symptoms, the spray supports general well-being and helps manage symptoms that interfere with daily comfort. It supports patients during episodes of heightened discomfort by providing supportive relief when symptoms become more noticeable.

Quick Fact: Relief for Acute Skin Discomfort
This topical solution is commonly used to help with symptoms arising from minor cuts, scrapes, minor sunburn, and insect bites.

Regulatory References

1. NIH MedlinePlus overview of Lidocaine Topical

Official Eligibility and Restrictions

The eligibility profile for Regenecare HA Spray, which contains the local anesthetic Lidocaine Hydrochloride, is defined by regulatory guidelines to prevent systemic exposure and toxicity.

Absolute Contraindications

The medicine is contraindicated and must not be used in patients with a known history of allergy or hypersensitivity to lidocaine or any other amide-type local anesthetic. Use is also contraindicated in patients with severe shock or severe heart block.

Restricted and Conditional Use

• Skin Integrity: The product must not be used on severely traumatized, infected, or non-intact skin in the area of application due to the high risk of increased systemic absorption.
• Age Limitations: The safety and efficacy for routine use are often not established in children under 12 years of age, and use in this group is typically restricted or not recommended without professional oversight. Elderly or acutely ill patients require caution and may have reduced tolerance.
• Health Conditions: Caution is mandatory for patients with severe hepatic disease because their impaired ability to metabolize lidocaine increases the risk of reaching toxic blood concentrations. Use also requires caution in patients with conditions like G6PD deficiency.
• Reproductive Status: Regulatory guidelines explicitly advise pregnant and breastfeeding women to consult a health professional before using the spray.

The interaction profile for Regenecare HA Spray is based on the systemic absorption potential of its active ingredient, Lidocaine, with regulatory documents defining specific pharmacokinetic and pharmacodynamic constraints. The following table summarizes officially documented interaction patterns:

Interaction Classification	Interacting Agents	Official Interaction Outcome
Contraindicated Co-administration	Class I Antiarrhythmic Agents	Risk of additive toxic effects on cardiac function.
Pharmacokinetic (Exposure)	CYP1A2 and CYP3A4 Inhibitors (e.g., Fluvoxamine, Erythromycin)	Increased systemic exposure and reduced clearance of the active ingredient.
Pharmacodynamic (Toxicity)	Other Local Anesthetic Agents and Oxidizing Agents	Additive toxicity, including heightened risk of methemoglobinemia.

Lidocaine’s metabolism is primarily dependent on the CYP1A2 and CYP3A4 enzyme systems, which is the basis for interaction severity with agents that inhibit these pathways. This pharmacokinetic interaction can lead to elevated systemic concentrations. Regulatory summaries note that substances such as Grapefruit Juice may increase systemic exposure, while substances like Cigarette Smoking may reduce the product’s efficacy.

Furthermore, patients with impaired hepatic function and infants 12 months or younger are officially recognized as populations with increased susceptibility to systemic interaction risks due to altered clearance or specific sensitivities. A procedural restriction is also noted: application to the mouth or throat requires that food ingestion be separated by at least 60 minutes to mitigate the documented risk of impaired swallowing and subsequent aspiration.

Peripheral Nociceptive Signal Blockade

This core action involves the Lidocaine component engaging and stabilizing voltage-gated sodium channels ( Na V channels) on peripheral nerve endings. By functionally blocking the rapid inward flow of sodium ions, the spray interrupts the electrical impulse generation and propagation along the nociceptive signaling pathway, resulting in the inhibition of localized sensory impulse transmission.

---

Modulation of Tissue Structure and Cellular Proliferation

The mechanism is augmented by components possessing inherent structural and cellular properties that modulate the environment of the compromised skin. Sodium Hyaluronate acts as a hydro-modulator, establishing a viscoelastic, highly moisturized layer optimal for cell migration and proliferation. This structural function, coupled with the Allantoin-mediated stimulation of fibroblast cells, influences the re-epithelialization rate and structural repair phases of the healing cascade.

---

Mechanistic Combination and Localized Effect

The overall function is defined by a dual-mechanism combination: the immediate interruption of nerve signaling enables the concomitant activity of the cellular components. The hydrogel base further acts as a specialized mechanistic vehicle, maintaining the physical contact time of the anesthetic with nerve endings while sustaining the environment needed for cellular repair processes, contributing to a localized physiological effect.

The administration of Regenecare HA Spray is characterized by specific patterns that define its usage. The medicine is designated for Topical (Cutaneous) application only, administered as a 2% Lidocaine Hydrochloride Hydrogel Spray. This route dictates that the product should only be applied to the surface of the skin.

---

The dosing regimen is based on the maximum frequency of application rather than a volumetric measure. The product is applied to the affected area not more than 3 to 4 times daily for temporary relief. This pattern establishes the drug's intended use as intermittent and as-needed, rather than a scheduled, long-term regimen.

Procedural guidelines indicate that the spray is for external use only. Administration involves specific contextual constraints to ensure usage: the product is not used in large quantities, particularly when applying to compromised skin surfaces such as raw areas or blisters.

Usage rules are defined by age group. The standard regimen of up to four applications daily applies to adults and children 2 years of age and older. For the youngest population, administration to children under 2 years of age involves a prior physician consultation. These descriptions collectively establish the method for the product's administration and application conditions.

Research evidence / Overview of Studies for Regenecare HA Spray

---

Evidence for Use in Temporary Relief of Minor Pain

The research landscape for this spray focuses on its primary component, topical Lidocaine, which was studied for application in conditions associated with acute or disruptive episodes of pain on the skin surface, such as minor cuts, scrapes, and first-degree sunburn. Research exploring this component relies on Systematic Reviews and Randomized Controlled Trials (RCTs) across various localized pain contexts.

Research primarily examined outcomes describing episodic or acute changes, including measurements of pain intensity and time to onset of reported physical discomfort. Studies conducted during periods of increased symptom activity reported patterns of change in pain perception measured shortly after application. The findings describe patterns observed in the studies that contribute to understanding symptom patterns during acute, localized episodes of discomfort.

While the core component was studied for application over a long period, comparative evidence is lacking for the spray versus other non-prescription options. Furthermore, the follow-up durations were limited, focusing on acute relief and generally not extending beyond a week. This means long-term effects are not fully established for managing recurrent pain symptoms with this product, and there is limited information for long-term outcomes or the durability of the reported changes over time.

---

Evidence for Use in Temporary Relief of Itching (Pruritus)

Research exploring the effect of topical anesthetic formulations on itching was evaluated in controlled studies, often during episodes where symptoms become more noticeable. These studies monitored patient-reported outcomes related to itch severity and perceived discomfort, for example, when associated with insect bites or minor skin irritations.

Studies reported how symptoms evolved in the observed populations, and findings indicated a temporary change in the sensation of itch. This research provides insight into short-term changes and contributes to the broader evidence landscape related to topical applications for pruritus.

---

Areas of Research Uncertainty and Study Gaps

A primary area of uncertainty is the lack of direct comparative evidence (e.g., dedicated head-to-head RCTs) for this specific combination hydrogel spray formulation against other existing over-the-counter topical pain relievers or anesthetics. Furthermore, evidence is limited in assessing the distinct impact of the secondary ingredients (Allantoin, Sodium Hyaluronate) when combined with Lidocaine in the acute pain and itch relief setting. The study data for various special populations, including younger children, remains insufficient.

Key Studies & References

1. Lidocaine Topical: MedlinePlus Drug Information

Common questions about Regenecare HA Spray (FAQ)

Q: Does Regenecare HA Spray help with redness and irritation?

A: According to official documents, the product is indicated for the temporary relief of minor pain and itching. However, redness ( erythema) and mild irritation are also documented in regulatory summaries as common local reactions that may occur at the site where the product is applied.

Q: Is Regenecare HA Spray considered a steroid?

A: No, Regenecare HA Spray is not classified as a steroid. Official regulatory documents confirm that the primary active ingredient, Lidocaine, belongs to the pharmacological class of amide-type local anesthetics.

Q: Has Regenecare HA Spray been studied in pregnant or breastfeeding populations?

A: Regulatory sources describe that the systemic absorption of Lidocaine is typically in tiny amounts. Despite this, official guidance explicitly advises that use during pregnancy or breastfeeding is officially stipulated to occur only after consultation with a healthcare professional.

Q: Is it normal to feel a tingling sensation after applying the spray?

A: The expected function of the product is to cause temporary numbness at the application site. Official information indicates that numbness is a common effect, and tingling is a related sensation often associated with the onset or ending of this localized change in feeling.

Q: How does Regenecare HA Spray differ from other hyaluronic acid products?

A: The fundamental difference lies in its primary classification. Regenecare HA Spray is officially classified as a Local Anesthetic, intended to relieve pain and itch using the Lidocaine component. In contrast, many other HA products are primarily classified as moisturizers or cosmetic aids.

Q: Can I apply other topical medications before or after using the spray?

A: Regulatory warnings specifically highlight the risk of additive toxicity when the product is co-administered with other local anesthetic agents. For all other prescription or over-the-counter topical medications, regulatory guidance refers patients to consultation with a healthcare professional regarding simultaneous use.

Q: Is it true that this spray helps with wound healing, as some people claim online?

A: The product is officially designated for the temporary relief of pain and itching. While one of the secondary ingredients, Sodium Hyaluronate, is noted in regulatory summaries to contribute structurally to re-epithelialization (a phase of healing), this is related to the ingredient's known function, not the product's primary use claim.

Q: Is Regenecare HA Spray safe to use on sensitive areas of the body?

A: Regulatory warnings state the spray is strictly for external use only. The product is officially designated not for application to the eyes, nose, or mouth area. Use is also restricted on large areas of skin, severely traumatized skin, or areas under occlusive dressings.

Q: What does 'HA' stand for in the name Regenecare HA Spray?

A: The acronym HA refers to Hyaluronic Acid ( or Hyaluronan). This component is included in the specialized hydrogel base to provide a supportive structural and moisturizing function.

Q: Do I need a prescription from a doctor to get Regenecare HA Spray?

A: Regulatory agencies have established concentration limits for topical Lidocaine products. Products containing Lidocaine at 2% concentration generally align with non-prescription ( OTC) availability. However, the specific legal status for this formulation is determined by the manufacturer's official labeling and local authority approval.

Q: Does Regenecare HA Spray expire, and if so, how quickly?

A: Yes, like all authorized drug products, the spray has an expiration date. Regulatory requirements mandate that the manufacturer establishes this official expiration date through stability testing, and the date is listed on the product packaging.

Q: What should I do if the spray accidentally gets into my eyes?

A: If the spray accidentally comes into contact with the eyes, regulatory safety data recommends immediately flushing the eyes with large amounts of water as a precaution. It is stipulated that medical attention be sought if irritation develops or persists after flushing.

Q: Does Regenecare HA Spray interact with common over-the-counter pain relievers?

A: Clinical interaction databases have not identified specific adverse interactions between topical Lidocaine and common over-the-counter oral pain relievers, such as ibuprofen. Nonetheless, official regulatory guidance refers patients to consultation with a healthcare professional regarding all co-administered medicines.

Q: Do studies exist that examine the use of Regenecare HA Spray in older adults?

A: Regulatory summaries note that older adults may have reduced tolerance to the product. Due to potential differences in metabolism and reduced tolerance for systemic exposure, the labeling notes that caution is necessary when use occurs in this population.

Q: Are there any reported interactions between Regenecare HA Spray and common herbal supplements?

A: Official regulatory guidance notes that information is often not available to determine the safety of using Lidocaine products with complementary medicines or herbal supplements. For this reason, official guidance refers patients to consultation with a healthcare professional before combining them.

Q: What should I do if I miss an application of the spray?

A: Since the product is designated for intermittent, as-needed use, a missed application may be applied as soon as it is remembered, provided the maximum daily frequency is not exceeded. It is stipulated that extra product should not be applied to make up for the missed application.

Q: Are there any specific cosmetic procedures that interfere with Regenecare HA Spray?

A: The FDA has issued warnings concerning the use of high-concentration topical anesthetics when applied before or during cosmetic procedures such as laser hair removal or tattooing. This is due to the potential risk of increased systemic absorption, and the information emphasizes that consultation with the treating professional is necessary.

Q: Does the use of Regenecare HA Spray require any special changes to my daily routine?

A: Beyond the general requirement to follow administration guidelines for frequency and amount, the only routine change specifically noted in procedural guidelines is the need to separate application near the mouth or throat from food ingestion by at least 60 minutes. This is a precaution against swallowing impairment.

How to Store and Dispose of Regenecare HA Spray?

Regenecare HA Spray (lidocaine HCl 2%) must be stored according to strict regulatory guidelines to maintain its stability and ensure safety.

Storage Requirements

The product is required to be stored at Controlled Room Temperature, specifically defined as a range between 68 F and 77 F (20 C to 25 C). It is mandatory to keep the container tightly closed when not in use and to store the spray in its original packaging. Storage environments must strictly avoid freezing and exposure to excessive heat.

Child Safety and Disposal

For child safety, the medicine must be stored out of the sight and reach of children at all times. Regarding disposal, unused or expired product should be taken to an authorized drug take-back program. If a take-back option is unavailable, the product may be disposed of in household trash only after being mixed with an unappealing substance like dirt or cat litter and sealed in a container.